Table 2.
Associations between two independent SNPs in the fatty acid synthesis pathway genes and CMSS of patients in the MDACC dataset, the NHS/HPFS dataset and the combined dataset of both MDACC and NHS/HPFS
| MDACC (n=858) | NHS/HPFS (n=409) | MDACC + NHS/HPFS (n=1267) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | Frequency | Multivariate analysis1 | Frequency | Multivariate analysis2 | Frequency | Multivariate analysis3 | ||||||
| All | Death (%) | HR (95% CI) | P | All | Death (%) | HR (95% CI) | P | All | Death (%) | HR (95% CI) | P | |
| ELOVL2 rs3734398 T>C | ||||||||||||
| TT | 310 | 40 (12.90) | 1.00 | 137 | 25 (18.25) | 1.00 | 447 | 65 (14.54) | 1.00 | |||
| TC | 385 | 42 (10.91) | 0.86 (0.55–1.35) | 0.515 | 201 | 19 (9.45) | 0.49 (0.27–0.89) | 0.019 | 586 | 61 (10.41) | 0.70 (0.50–1.00) | 0.049 |
| CC | 163 | 13 (7.98) | 0.45 (0.23–0.89) | 0.021 | 71 | 4 (5.63) | 0.31 (0.11–0.90) | 0.030 | 234 | 17 (7.26) | 0.48 (0.28–0.82) | 0.007 |
| Trend test | 0.027 | 0.005 | 0.003 | |||||||||
| TC+CC | 548 | 55 (10.04) | 0.72 (0.47–1.10) | 0.128 | 272 | 23 (8.46) | 0.44 (0.25–0.78) | 0.005 | 820 | 78 (9.51) | 0.64 (0.46–0.89) | 0.007 |
| HSD17B12 rs11037684 A>G | ||||||||||||
| AA | 757 | 79 (10.44) | 1.00 | 360 | 36 (10.00) | 1.00 | 1117 | 115 (10.30) | 1.00 | |||
| AG | 99 | 16 (16.16) | 2.23 (1.28–3.91) | 0.005 | 46 | 11 (23.91) | 2.70 (1.37–5.31) | 0.004 | 145 | 27 (18.62) | 1.98 (1.30–3.02) | 0.002 |
| GG | 2 | 0 (0.00) | - | - | 3 | 1 (33.33) | 4.80 (0.63–36.45) | 0.130 | 5 | 1 (20.00) | 1.66 (0.23–11.97) | 0.613 |
| Trend test | 0.007 | 0.002 | 0.002 | |||||||||
| AG+GG | 101 | 16 (15.84) | 2.21 (1.26–3.86) | 0.006 | 49 | 12 (24.49) | 2.80 (1.45–5.39) | 0.002 | 150 | 28 (18.67) | 1.97 (1.30–2.98) | 0.001 |
| Combined number of risk genotypes4 | ||||||||||||
| 0 | 489 | 46 (9.41) | 1.00 | 240 | 17 (7.08) | 1.00 | 729 | 63 (8.64) | 1.00 | |||
| 1 | 327 | 42 (12.84) | 1.56 (1.00–2.41) | 0.048 | 152 | 25 (16.45) | 2.52 (1.36–4.67) | 0.004 | 479 | 67 (13.99) | 1.67 (1.19–2.36) | 0.003 |
| 2 | 42 | 7 (16.67) | 2.70 (1.18–6.18) | 0.019 | 17 | 6 (35.29) | 5.55 (2.19–14.08) | 0.0003 | 59 | 13 (22.03) | 2.85 (1.57–5.18) | 0.0006 |
| Trend test | 0.007 | <.0001 | <.0001 | |||||||||
| 0 | 489 | 46 (9.41) | 1.00 | 240 | 17 (7.08) | 1.00 | 729 | 63 (8.64) | 1.00 | |||
| 1–2 | 369 | 49 (13.28) | 1.66 (1.09–2.53) | 0.019 | 169 | 31 (18.34) | 2.82 (1.56–5.10) | 0.0006 | 538 | 80 (14.87) | 1.79 (1.29–2.50) | 0.0005 |
Abbreviations: SNP, single-nucleotide polymorphism; CMSS, cutaneous melanoma-specific survival; MDACC, The University of Texas MD Anderson Cancer Center; NHS/HPFS, the Nurses’ Health Study and Health Professionals Follow-up Study; HR, hazards ratio; CI, confidence interval; ELOVL2, elongation of very long-chain fatty acids 2; HSD17B12, hydroxysteroid dehydrogenase type 12;
Adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in the MDACC dataset;
Adjusted for age and sex in the NHS/HPFS dataset;
Adjusted for age and sex in the combined dataset of both MDACC and NHS/HPFS;
Risk genotypes include ELOVL2 rs3734398 TT and HSD17B12 rs11037684 AG+GG.